Stay updated on Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for the pembrolizumab study in nasopharyngeal carcinoma, including its study design, eligibility criteria, outcomes, status, and dates.
    Difference
    48%
    Check dated 2026-11-07T15:47:45.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site footer now identifies the ClinicalTrials.gov release as v3.8.0 instead of v3.7.2; the study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T16:14:10.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says “Super Intelligence” is being used in place of “Artificial Intelligence” across NIH content. It appears above the study record’s 403 error.
    Difference
    1%
    Check dated 2026-10-24T18:18:59.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T19:44:09.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T20:23:54.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content. This removes access to the trial details and related information, leaving only site boilerplate and an error message.
    Difference
    18%
    Check dated 2026-09-19T22:01:16.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page.